Generic Fosrenol Availability

Fosrenol is a brand name of lanthanum carbonate, approved by the FDA in the following formulation(s):

FOSRENOL (lanthanum carbonate - tablet, chewable;oral)

  • Manufacturer: SHIRE LLC
    Approval date: October 26, 2004
    Strength(s): EQ 500MG BASE
  • Manufacturer: SHIRE LLC
    Approval date: November 23, 2005
    Strength(s): EQ 1GM BASE [RLD], EQ 750MG BASE

Has a generic version of Fosrenol been approved?

No. There is currently no therapeutically equivalent version of Fosrenol available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fosrenol. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Pharmaceutical composition containing selected lanthanum carbonate hydrates
    Patent 5,968,976
    Issued: October 19, 1999
    Inventor(s): Murrer; Barry A & Powell; Nigel A
    Assignee(s): AnorMed Inc.
    Selected lanthanum carbonate hydrates may be administered into the gastrointestinal tract, to treat hyperphosphataemia in patients with renal failure.
    Patent expiration dates:
    • October 26, 2018
      Drug product
  • Stabilized lanthanum carbonate compositions
    Patent 7,381,428
    Issued: June 3, 2008
    Inventor(s): Ferdinando; Josephine Christine & Davies; Peter Neil
    Assignee(s): Shire International Licensing B.V.
    Stabilized lanthanum carbonate compositions containing a monosaccharide or disaccharide stabilizing agent are disclosed. Subjects having hyperphosphatemia can be treated by administering a pharmaceutical composition containing a therapeutically effective amount of the stabilized lanthanum carbonate formulation.
    Patent expiration dates:
    • August 26, 2024
  • Pharmaceutical formulation comprising lanthanum compounds
    Patent 7,465,465
    Issued: December 16, 2008
    Inventor(s): Haslam; Robert Paul & Trespidi; Laura Anna & Ferdinando; Josephine Christine
    Assignee(s): Shire Biochem Inc.
    This invention relates to a chewable lanthanum formulation comprising a pharmaceutically effective amount of a lanthanum compound; and at least one chewable pharmaceutically acceptable excipient. This invention also relates to a pharmaceutical formulation in a tablet or in a powder comprising a pharmaceutically effective amount of a lanthanum compound produced by a process which comprises the steps of: a) powder blending the lanthanum compound and at least one pharmaceutically acceptable excipient in a mixer to form a mixture; or b) powder blending the lanthanum compound and excipients, compressing the resulting combination into a slug material or roller compacting the resulting combination into a strand material, and milling the prepared material into a free flowing mixture; and c) compressing the resulting mixture into a tablet or filing up the resulting mixture in a appropriate container.
    Patent expiration dates:
    • August 26, 2024
      Drug product


Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.